BCIwiki — Brain-computer interface news, research and industry database

University of British Columbia researchers released BEND-BCI, an open benchmark comparing 23 neural decoders across 16 real or synthetic recordings in motor, visual, speech and spatial tasks. Rankings often changed when robustness, computational cost and cross-recording representation consistency were considered alongside held-out accuracy, and simpler baselines sometimes matched or beat much larger deep networks. The bioRxiv preprint has not been peer reviewed.

ATCNet-CIAM, a decoder pairing temporal convolution and channel attention with a CIAM module, reached 86.32% accuracy on BCI IV-2a and 87.96% on BCI IV-2b under the standard protocol, its authors report, along with 89.46% and 83.64% on the within-session two-class and three-class WBCIC-MI tasks. Motor imagery EEG is the workhorse signal for non-invasive brain-computer interfaces, but decoding it robustly across sessions and subjects remains the central obstacle. The manuscript was posted to arXiv on July 26, 2026 and has not been peer reviewed; it has been accepted for the International Conference on Intelligence Systems and Robotics for Sustainable Development (ISRSD) 2026.

A preprint proposes an adaptive EEG generation framework based on conditional flow matching to ease data scarcity in brain-computer interfaces and support large-scale neural modeling. Noting that existing flow methods assume one global time course across all channels and time segments, the framework adds position-adaptive time scheduling that tracks per-position reconstruction error to modulate each position's time course, plus decomposed spatiotemporal attention and a frequency-aligned multi-resolution spectral consistency loss to model cross-channel dependencies and compensate for EEG's power-law spectral bias. Across three EEG datasets with different acquisition protocols and task semantics, it consistently beat the strongest baselines, cutting TS-FID by up to 62.2% and lifting downstream classification accuracy by up to 6.77 percentage points. The study has not been peer reviewed.

Researchers report a preprint, posted to arXiv on July 25, 2026 and not yet peer reviewed, that contrasts Bayesian complete-pooling models against frequentist baselines for cross-subject, left-hand versus right-hand motor imagery EEG classification across 20 datasets. Six frequentist pipelines were each paired with an analogous Bayesian pipeline sharing identical feature engineering and fit via Markov chain Monte Carlo posterior sampling. Bayesian complete-pooling produced statistically but not practically significant improvements in reliability and increased predictive uncertainty, with no significant differences in Brier score, resolution, or discrimination. Bayesian pipelines consumed roughly 13 times more energy than their frequentist counterparts, and the authors conclude that complete pooling alone offers limited practical benefit, pointing to partial pooling as a more promising direction.

A registry-based cross-sectional analysis found only 11 pediatric brain-computer interface (pBCI) clinical trials worldwide, spanning 7 countries. Eight evaluated non-implanted devices and 3 evaluated implanted systems. Non-implanted trials had a median enrollment of 29 participants and median duration of 56.0 days; implanted trials had a median enrollment of 8 and median duration of 365.3 days. Only 4 studies enrolled exclusively pediatric participants; the rest recruited both children and adults. The authors conclude that current pBCI research is limited in scope and that children may be inadequately prioritized.

The researchers developed a deep learning architecture that analyzes multichannel interictal intracranial EEG to localize epileptogenic zones without requiring seizure-period recordings or manual annotation. The model combines a Morlet-wavelet temporal Transformer with a spatial attention encoder. It was evaluated with 50.5 hours of recordings from 161 patients and 17,012 channels at 7 independent centers. Leave-one-center-out validation produced a pooled AUROC of 0.778 with a 95% confidence interval of 0.748 to 0.808, and discrimination remained above chance at every held-out center. The results indicate performance comparable to established electrophysiological baselines across centers and implantation modalities, but prospective clinical validation is still needed. This medRxiv preprint has not been peer reviewed.

An arXiv preprint introduces fMRI-Face, a Full-HD fMRI-video dataset, and fMRI2Face, a geometry-guided framework for reconstructing dynamic faces from brain activity. The method combines brain-derived appearance context with morphable 3D facial control in a neural-controlled video-diffusion pipeline. The work has not been peer reviewed.

Researchers ran 11 healthy participants through a personalized rapid serial auditory presentation paradigm and decoded the resulting weak auditory evoked responses trial by trial with a new model, the Multi-Scale Spatial-Temporal Dual Attention Network (MS-STAMNet), reaching an unweighted average recall of 69.67±6.12% and an AUC of 0.7618±0.07, ahead of the EEGNet and PLNet baselines. Conventional measurement of the auditory frequency difference limen (FDL) depends on participants actively reporting what they hear, which leaves it open to subjective bias. Regression analysis found that neural decoding and behavioral performance came apart, suggesting the model picks up frequency deviations too small to reach conscious report.

Placing electrodes on the brain's surface rather than inserting them into tissue is the key difference between Precision Neuroscience's approach and the BrainGate approach Donoghue pioneered. The New York-based company develops minimally invasive, safely removable, high-bandwidth BCIs; its first system, Layer 7, is aimed at people with ALS, spinal cord injury and brainstem stroke, a population the company estimates at 315,000 in the US. The company says its Layer 7 cortical surface array has been implanted in nearly 100 patients at several leading academic medical centers, that it has raised $180 million from investors, and that it has received FDA 510(k) clearance. Donoghue, a professor emeritus at Brown University, will advise on device design, signal decoding and clinical strategy as the company pushes ahead with a long-term implant study and commercial launch.